Key takeaways
Foundayo (orforglipron) and Wegovy (semaglutide) are both medications in the GLP-1 agonist class, used to help with weight loss and long-term weight management. They work by slowing digestion, helping you feel fuller, and controlling your appetite. However, they have some differences. Foundayo is taken as a daily oral tablet, while Wegovy is available as a weekly injection or a daily tablet. Wegovy is also approved for additional uses, such as reducing the risk of heart attack and treating metabolic dysfunction-associated steatohepatitis (MASH), while Foundayo is not. Foundayo is only approved for adults, whereas Wegovy can be used by children aged 12 and older. Common side effects for both include nausea and stomach pain, but Wegovy has a higher reported rate of nausea. Both medications have a potential risk for thyroid cancer, so they should not be used by people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2.
